Subjects who carry mutations in breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2 genes) are at higher risk of developing cancers. Despite the cumulative amount of evidence published in the literature in the last two decades, the management of BRCA mutation carriers is still not completely defined. Since the prevalence of the mutation is estimated to be 1:400 - 1:500 individuals, the total number of BRCA mutation carriers should be around 140.000 - 150.000 in the Italian population. It is estimated that 87% of women with BRCA mutations will experience, in their lifetime, a tumor with a genetic origin. About 20% of the 5200 ovarian cancer cases diagnosed each year in Italy has a genetic origin and could potentially be the object of primary prevention. To date, and to the best of our knowledge, a national prospective data collection on women with BRCA mutations has not been yet established.
Study Type
OBSERVATIONAL
Enrollment
10,000
Registration of clinical datas in the platform of female individual carrying a BRCA1 or BRCA2 mutation
Malzoni Research Hospital
Avellino, Italy
NOT_YET_RECRUITINGCentro di Riferimento Oncologico IRCCS
Aviano, Italy
NOT_YET_RECRUITINGUniversità degli Studi di Bari "Aldo Moro"
Bari, Italy
NOT_YET_RECRUITINGIRCCS Istituto Tumori "Giovanni Paolo II"
Bari, Italy
RECRUITINGCollection data about BRCA mutation
To collect data of each female individual carrying a BRCA1 or BRCA2 mutation
Time frame: 1 day
GEOGRAPHICAL DISTRIBUTION OF BRCA MUTATIONS
GEOGRAPHICAL DISTRIBUTION OF BRCA MUTATIONS FOR IDENTIFY THE AREAS WHERE THE INCIDENCE OF THE MUTATION IS HIGHER THAN EXPECTED
Time frame: 6 months
CENTRALIZATION OF CASES IN HIGHLY SPECIALIZED CENTERS
CENTRALIZATION OF CASES IN HIGHLY SPECIALIZED CENTERS FOR THE PREVENTION AND TREATMENT OF GENETIC-RELATED CANCER
Time frame: 6 months
RELATIONSHIP BETWEEN SPECIFIC MUTATIONS AND SPECIFIC TYPES OF CANCER
DEFINITION OF THE RELATIONSHIP BETWEEN SPECIFIC MUTATIONS AND THE ONSET OF SPECIFIC TYPES OF CANCER
Time frame: 6 months
CRITERIA FOR DETERMINING THE ACCESS TO GENETIC EVALUATION
EVALUATION OF THE ADEQUACY OF THE CRITERIA FOR DETERMINING THE ACCESS TO GENETIC EVALUATION
Time frame: 6 months
LIFESTYLE RISK FACTORS
DEFINITION OF LIFESTYLE RISK FACTORS FOR THE DEVELOPMENT OF TUMORS IN BRCA MUTATION CARRIERS
Time frame: 6 months
DEFINITION OF PREVENTIVE STRATEGIES
HEALTHY SUBJECTS: DEFINITION OF RISK REDUCING OR PREVENTIVE STRATEGIES
Time frame: 6 months
Risk-reducing salpingo-oophorectomy
MANAGEMENT OF WOMEN AFTER RRSO (risk-reducing salpingo-oophorectomy) AFTER SURGERY
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
ASST Papa Giovanni XXIII
Bergamo, Italy
NOT_YET_RECRUITINGL'Azienda ospedaliera per l'emergenza "Cannizzaro"
Catania, Italy
NOT_YET_RECRUITINGAzienda Ospedaliero Santa Croce e Carle
Cuneo, Italy
NOT_YET_RECRUITINGPresidio Ospedaliero Umberto I - ASP di Enna
Enna, Italy
NOT_YET_RECRUITINGAzienda Ospedaliero Universitaria Careggi, Oncologia Medica Ginecologica
Florence, Italy
NOT_YET_RECRUITINGIRCCS Ospedale Policlinico San Martino
Genova, Italy
NOT_YET_RECRUITING...and 30 more locations